Schedule 13G ownership disclosure
Inhibikase Therapeutics Inc
Common Stock, $0.001 par value · CUSIP: 45719W205
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Perceptive Advisors LLC
Shares: 12,816,643 · Class: 9.99%
- Joseph Edelman
Shares: 12,816,643 · Class: 9.99%
- Perceptive Life Sciences Master Fund, Ltd.
Shares: 12,816,643 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-054524
- Form type
- SCHEDULE 13G/A
- Filer
- Inhibikase Therapeutics, Inc.
- CIK
- CIK 1750149
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership